The Pleiotropic Effects of Antihypertensive Agents: Do They Account for Additional Cardiovascular Benefit Beyond BP Reduction?

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Southern medical journal (Birmingham, Ala. Print)

• Publication date

  2008-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/SMJ.0b013e31817b6622PMID 18622353
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Markers of Inflammation and Cardiovascular Disease

  2009cited by this paper
• Aldosterone Suppresses Insulin Signaling Via the Downregulation of Insulin Receptor Substrate-1 in Vascular Smooth Muscle Cells

  2007cited by this paper
• Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.

  2007cited by this paper
• Mineralocorticoid Receptor Blockade Improves Vasomotor Dysfunction and Vascular Oxidative Stress Early After Myocardial Infarction

  2007cited by this paper
• Central blood pressures: do we need them in the management of cardiovascular disease? Is it a feasible therapeutic target?

  2007cited by this paper
• Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).

  2007cited by this paper
• Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure

  2007cited by this paper
• Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade

  2007cited by this paper
• The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).

  2006influential reference
• Angiotensin II-Induced Hypertension and Subsequent Renal Pathology is Attenuated in Mice Lacking Soluble Epoxide Hydrolase: P31

  2006cited by this paper
• Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study

  2006cited by this paper
• Prevention of Cardiovascular Events With an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required Versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Tri

  2006cited by this paper
• Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension

  2006cited by this paper
• Blood Pressure Reduction Is Not the Only Determinant of Outcome

  2006cited by this paper
• Effect of ramipril on the incidence of diabetes.

  2006cited by this paper
• The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy

  2006cited by this paper
• Stroke and coronary heart disease in treated hypertension – a prospective cohort study over three decades

  2005cited by this paper
• Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis

  2005cited by this paper
• Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling

  2005cited by this paper
• Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri

  2005cited by this paper
• Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES)

  2005cited by this paper
• Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells

  2004cited by this paper
• From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension.

  2004cited by this paper
• Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.

  2004cited by this paper
• Imidapril improves l-NAME-exacerbated nephrosclerosis with TGF-β1 inhibition in spontaneously hypertensive rats

  2004cited by this paper
• Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis: Results of a Randomized Trial

  2004cited by this paper
• Effect of the renin–angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function

  2004cited by this paper
• Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome

  2004cited by this paper
• Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis

  2004cited by this paper
• Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

  2004influential reference
• Hypertension, transforming growth factor-beta, angiotensin II and kidney disease.

  2004cited by this paper
• Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease.

  2004cited by this paper
• P-219: The effects of valsartan HCT versus amlodipine on inflammatory markers in hypertensive African Americans: The advance trial

  2004cited by this paper
• Hypertension, transforming growth factor- , angiotensin II and kidney disease

  2004influential reference
• Analysis of Recent Papers in Hypertension

  2004cited by this paper
• Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

  2003cited by this paper
• MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION

  2003cited by this paper
• JNC 7--it's more than high blood pressure.

  2003cited by this paper
• Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.

  2003cited by this paper
• Maintenance of normal blood pressure and renal functions are independent effects of angiotensin-converting enzyme.

  2003cited by this paper
• Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

  2003cited by this paper
• Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

  2003cited by this paper
• Calcium Antagonists and Atherosclerosis Protection in Hypertension

  2003cited by this paper
• The EUROPA trial

  2003cited by this paper
• Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

  2003cited by this paper
• Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

  2002cited by this paper
• Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial

  2002cited by this paper
• Clinical trials report

  2001cited by this paper
• Blood-pressure reduction and cardiovascular risk in HOPE study.

  2001cited by this paper
• Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures: A HOPE Substudy

  2001cited by this paper
• Inhibition of platelet aggregability by losartan in essential hypertension.

  2000cited by this paper
• Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Angiotensin-converting enzyme expression in human carotid artery atherosclerosis.

  2000cited by this paper
• Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications.

  1996influential reference
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Comparison of the Effect of Fimasartan versus Valsartan on Blood Pressure Variability in Acute Ischemic Stroke: A Double-Blind Randomized Trial

  2019cites this paper
• The “Rise–Peak–Fall” Pattern of Time Dependency of the Cardiovascular Pleiotropic Effects of Treatment With Low-dose Atorvastatin, Losartan, and a Combination Thereof in Rats

  2016cites this paper
• Re: "a prospective study of statin drug use and lower urinary tract symptoms in older men".

  2014cites this paper
• Telmisartan Exerts Pleiotropic Effects in Endothelial Cells and Promotes Endothelial Cell Quiescence and Survival

  2013cites this paper
• Reduction of age-associated arterial wall changes by low-dose valsartan

  2012cites this paper
• ASPECTS OF THE AMLODIPINE PLEIOTROPY IN BIOCHEMISTRY, PHARMACOLOGY AND CLINICS

  2012cites this paper
• Combination Therapy for Managing Difficult-to-Treat Patients With Stage 2 Hypertension: Focus on Valsartan-Based Combinations

  2011cites this paper
• Antihypertensive agents: are all of them equal?

  2008cites this paper
• Letters to the Editor Re: " a Prospective Study of Statin Drug Use and Lower Urinary Tract Symptoms in Older Men "

  year unknowncites this paper